Morgan Stanley’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$14.2B Sell
15,437,458
-155,561
-1% -$158M 0.86% 14
2025
Q4
$16.8B Buy
15,593,019
+407,166
+3% +$389M 1% 11
2025
Q3
$11.6B Buy
15,185,853
+317,357
+2% +$236M 0.7% 18
2025
Q2
$11.6B Sell
14,868,496
-5,870
-0% -$4.56M 0.76% 17
2025
Q1
$12.3B Buy
14,874,366
+495,270
+3% +$412M 0.88% 14
2024
Q4
$11.1B Sell
14,379,096
-177,046
-1% -$147M 0.78% 16
2024
Q3
$12.9B Buy
14,556,142
+834,139
+6% +$750M 0.94% 11
2024
Q2
$12.4B Buy
13,722,003
+652,440
+5% +$522M 0.96% 11
2024
Q1
$10.2B Sell
13,069,563
-12,251,871
-48% -$8.72B 0.82% 13
2023
Q4
$14.8B Buy
25,321,434
+12,775,862
+102% +$7.46B 0.65% 19
2023
Q3
$6.74B Buy
12,545,572
+83,915
+0.7% +$43.2M 0.69% 15
2023
Q2
$5.84B Buy
12,461,657
+318,198
+3% +$133M 0.58% 23
2023
Q1
$4.17B Buy
12,143,459
+84,255
+0.7% +$28.4M 0.45% 37
2022
Q4
$4.41B Buy
12,059,204
+3,691,436
+44% +$1.31B 0.5% 30
2022
Q3
$2.71B Buy
8,367,768
+864,625
+12% +$274M 0.37% 50
2022
Q2
$2.43B Buy
7,503,143
+3,529,744
+89% +$1.06B 0.32% 59
2022
Q1
$1.14B Buy
3,973,399
+150,539
+4% +$38.7M 0.15% 146
2021
Q4
$1.06B Buy
3,822,860
+44,831
+1% +$11.4M 0.13% 165
2021
Q3
$873M Sell
3,778,029
-44,790
-1% -$11.1M 0.12% 179
2021
Q2
$877M Buy
3,822,819
+289,490
+8% +$58.2M 0.12% 178
2021
Q1
$660M Buy
3,533,329
+155,365
+5% +$30.4M 0.1% 202
2020
Q4
$570M Buy
3,377,964
+365,026
+12% +$54.5M 0.09% 206
2020
Q3
$446M Buy
3,012,938
+265,526
+10% +$41.1M 0.09% 209
2020
Q2
$451M Sell
2,747,412
-122,639
-4% -$18.8M 0.1% 188
2020
Q1
$398M Sell
2,870,051
-381,494
-12% -$52.4M 0.11% 180
2019
Q4
$427M Buy
3,251,545
+646,274
+25% +$74.9M 0.1% 197
2019
Q3
$291M Sell
2,605,271
-512,017
-16% -$57M 0.08% 250
2019
Q2
$345M Sell
3,117,288
-1,406,626
-31% -$166M 0.09% 221
2019
Q1
$587M Buy
4,523,914
+441,533
+11% +$53.7M 0.17% 134
2018
Q4
$472M Sell
4,082,381
-628,314
-13% -$70.2M 0.14% 155
2018
Q3
$506M Buy
4,710,695
+237,158
+5% +$23.7M 0.13% 165
2018
Q2
$382M Buy
4,473,537
+1,227,888
+38% +$101M 0.1% 203
2018
Q1
$251M Sell
3,245,649
-2,197,040
-40% -$177M 0.07% 278
2017
Q4
$460M Buy
5,442,689
+584,222
+12% +$49.7M 0.13% 168
2017
Q3
$416M Buy
4,858,467
+41,855
+0.9% +$3.43M 0.12% 174
2017
Q2
$396M Buy
4,816,612
+128,251
+3% +$10.5M 0.12% 181
2017
Q1
$394M Buy
4,688,361
+663,263
+16% +$53.1M 0.12% 180
2016
Q4
$296M Buy
4,025,098
+985,762
+32% +$73.4M 0.1% 220
2016
Q3
$244M Buy
3,039,336
+238,661
+9% +$19.1M 0.08% 269
2016
Q2
$221M Sell
2,800,675
-579,569
-17% -$43.6M 0.08% 276
2016
Q1
$243M Sell
3,380,244
-130,154
-4% -$9.85M 0.09% 242
2015
Q4
$296M Buy
3,510,398
+459,759
+15% +$38.2M 0.11% 215
2015
Q3
$255M Sell
3,050,639
-601,096
-16% -$50.7M 0.09% 238
2015
Q2
$305M Buy
3,651,735
+37,553
+1% +$2.86M 0.11% 218
2015
Q1
$263M Buy
3,614,182
+69,155
+2% +$4.92M 0.1% 243
2014
Q4
$245M Buy
3,545,027
+914,097
+35% +$61.7M 0.09% 252
2014
Q3
$171M Sell
2,630,930
-58,068
-2% -$3.68M 0.07% 326
2014
Q2
$167M Buy
2,688,998
+288,573
+12% +$17.2M 0.07% 330
2014
Q1
$141M Sell
2,400,425
-598,127
-20% -$33.4M 0.06% 360
2013
Q4
$153M Sell
2,998,552
-667,191
-18% -$33.4M 0.07% 332
2013
Q3
$184M Sell
3,665,743
-981,484
-21% -$51.4M 0.09% 254
2013
Q2
$228M Buy
+4,647,227
New +$253M 0.12% 215

Other funds holding LLY

Morgan Stanley's LLY Position: Q1 2026 in Review

Morgan Stanley reduced its Eli Lilly (LLY) stake by 1% in Q1 2026, selling an estimated $158M and leaving 15,437,458 shares worth $14.2B. The position accounts for 0.86% of the portfolio, ranked #14.

Morgan Stanley first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $16.8B in Q4 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Morgan Stanley held 15,437,458 shares of Eli Lilly worth $14.2B as of Q1 2026.
  • Morgan Stanley sold 155,561 Eli Lilly shares in Q1 2026, an estimated $158M.
  • Eli Lilly made up 0.86% of Morgan Stanley's portfolio in Q1 2026, its #14 holding.
  • Morgan Stanley first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Morgan Stanley's Eli Lilly position peaked at $16.8B in Q4 2025.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.